… signaling pathways driving epithelial-to-mesenchymal transition and insulin-like growth factor
1 (IGF1)/IGF1 receptor … with AJCC stage II, III, or IV disease without distant metastasis (n = …

… , JK Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor–1
signaling in metastatic … of gemcitabine, erlotinib, and cixutumumab versus gemcitabine …

… next four leading causes of cancer (colon/rectal, breast, pancreas, and prostate) … epithelial
cells of segmental bronchi. For stage IV NSCLC cancers, the incidence of distant metastasis to …

Pancreatic cancer (PaCA) has a dismal survival of 9%. Current therapies, including standard-of-care
gemcitabine (Gem)-based therapies, are not effective. Gem alone provides only …

… activation of the insulin-like growth factor receptor 1 system, … (com els inhibidors tirosina
quinasa gefitinib i erlotinib o l’anticòs … arm compared to cixutumumab single agent would support …

… Erlotinib is already approved for the treatment of metastatic … the monoclonal antibody A12,
cixutumumab and AVE 1642) are … Phase II study of gemcitabine and oxaliplatin in combination …

… In a phase II study, onartuzumab and erlotinib combination … in response to gemcitabine-induced
cytotoxicity [177]. … monoclonal antibody to insulin-like growth factor receptor 1. J Clin …

… Dual DVL and DAB2 blockade synergized in activating ERKs … Type 1 insulin-like growth
factor 1 receptor (IGFIR) signals … protects from tumor development and metastasis, suggesting …

… ) erlotinib, which targets the epidermal growth factor receptor (… with cixutumumab and patients
are randomized to gemcitabine… insulinlike growth factor receptor-1 (IGFR-1) and epidermal …

… In addition, combinations of gemcitabine with erlotinib or … IGF-R1 antibody cixutumumab
plus temsirolimus in 26 patients, … with unresectable recurrent or metastatic disease. Disease …